Publications by authors named "Thomas Habermann"

Claim this Profile
G
Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses.
Amy Moore, Eleanor Kane, Lauren R Teras, Mitchell J Machiela, Joshua Arias, Thomas M Habermann

Int J Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance Study.
Yoshito Nishimura, Thomas Habermann, Angela Dispenzieri

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study.
Nadia Toumeh, Melissa Larson, Brianna Negaard, Carla Casulo, Sairah Ahmed, Thomas Habermann

Leuk Lymphoma· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single-institution retrospective study of 66 patients.
Suheil Albert Atallah-Yunes, Matthew J Rees, Thomas M Habermann, Yucai Wang, Javier Munoz

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.
Suheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, Matthew J Rees, Juan Pablo Alderuccio, Thomas M Habermann

Am J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.
Colleen A Ramsower, George Wright, Hongli Li, James R Cerhan, Matthew J Maurer, Thomas M Habermann

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.
Matthew J Maurer, Vit K Prochazka, Tarec Christoffer El-Galaly, Christopher R Flowers, Diego Villa, Thomas M Habermann

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort Study.
Yoshito Nishimura, Thomas M Habermann, Morie A Gertz, Luis Porrata, Patrick B Johnston

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of genome-wide association studies of doxorubicin-induced arrhythmia identifies and as risk loci.
Joseph S Reddy, Milagros Pereyra, Mohammed Tiseer Abbas, Reza Arsanjani, Isaac E Prah, Thomas M Habermann

medRxiv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo Clinic.
Ahmed Alnughmush, Suheil Albert Atallah-Yunes, Tamer Hellou, Thomas M Habermann, Yucai Wang

Am J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.
Suheil Albert Atallah-Yunes, Arushi Khurana, Thomas M Habermann

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort.
James R Cerhan, Tereza Sokolova, Elliott J Cahn, Mazie Tsang, Christopher S Strouse, Thomas M Habermann

Hematol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Radiation Therapy in the Management of Gray Zone Lymphoma.
Omran Saifi, Scott C Lester, Nadia Laack, William G Rule, William G Breen, Thomas Habermann

Int J Radiat Oncol Biol Phys· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis, Thomas M Habermann

J Natl Compr Canc Netw· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity.
Suheil Albert Atallah-Yunes, Thomas M Habermann, Matthew J Rees, Lay She Ng, Urshila Durani

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Grade B-Cell Neurolymphomatosis: A Case Series and Diagnostic Insight.
Ken Porche, Rebecca L King, Thomas M Habermann, Patrick B Johnston, Robert J Spinner

World Neurosurg· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts.
Patrizia Mondello, Brianna Negaard, Andrew L Feldman, Brian K Link, Carla Casulo, Thomas M Habermann

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.
Suheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, Robyn L Kuchler, Ahmed Alnughmush, Thomas M Habermann

Blood Cancer J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma.
Janek S Walker, Kerstin Wenzl, Joseph P Novak, Matthew E Stokes, Melissa A Hopper, Thomas M Habermann

Blood Cancer J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia.
Jonas Paludo, Jithma P Abeykoon, Nirosha D Perera, Shayna Sarosiek, Joshua Gustine, Thomas M Habermann

Am J Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series.
Gita Thanarajasingam, Ajay Major, Vishal Bhatnagar, Amylou C Dueck, Karin E Smedby, Thomas Habermann

Lancet Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin.
Geffen Kleinstern, Dennis P Robinson, Lisa M Rimsza, Melissa C Larson, Rebecca L King, Thomas M Habermann

Cancer Epidemiol Biomarkers Prev· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Loretta J Nastoupil, Clark R Andersen, Amy Ayers, Yucai Wang, Thomas M Habermann

Clin Lymphoma Myeloma Leuk· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of lymphoid malignancy associated with cancer predisposition genes.
Nicholas J Boddicker, Raphael Mwangi, Dennis P Robinson, Cristine Allmer, Allison C Rosenthal, Thomas M Habermann

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience.
Steven R Hwang, Richard C Godby, Brianna J Negaard, Raphael Mwangi, Adrienne N Nedved, Thomas M Habermann

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis